TITLE

Extensive Coronary Collateral Formation in a Patient with Untreated Acromegaly

AUTHOR(S)
Goldberg, Emanuel; Berger, Marvin; Garber, Michael
PUB. DATE
May 1983
SOURCE
Angiology;May1983, Vol. 34 Issue 5, p306
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A case of acromegaly with extensive coronary collateralization is reported. Growth hormone may have played a role in this neovascularization.
ACCESSION #
16388217

 

Related Articles

  • Clinical Review: Acromegaly. Reddy, Raghava; Wass, John // GP: General Practitioner;5/20/2011, p33 

    The article offers information on a chronic metabolic disorder, acromegaly. Its caused when the anterior pituitary gland produces excess growth hormone (GH). The somatic and metabolic effects of acromegaly include stimulation of growth of many tissues, and insulin antagonism and lipolysis. The...

  • Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Plöckinger, U.; Quabbe, H.-J. // Acta Neurochirurgica;May2005, Vol. 147 Issue 5, p485 

    Background. The effect of presurgical long-acting somatostatin analogue (SSA) treatment on operative outcome in acromegaly is as yet uncertain and long-term observations are lacking. We evaluated in an acromegaly case-control study the effect of octreotide pre-treatment on short- and long-term...

  • Pituitary Apoplexy in a Patient with Acromegaly. Pieper, William J.; Ryan, Robert J. // Annals of Internal Medicine;Sep61, Vol. 55 Issue 3, p478 

    Reports on a case of pituitary apoplexy in a 43-year-old single white female with acromegaly. Medical history of the patient; Clinical manifestations of the disease; Methods of diagnosis and treatment.

  • Modern treatment of acromegaly. Merza, Z. // Postgraduate Medical Journal;Apr2003, Vol. 79 Issue 930, p189 

    Examines the efficacy of some of the methods which was used for treating acromegaly. Effect of different dopaminergic agents in the treatment of acromegaly; Disadvantages of pituitary radiotherapy in the treatment of acromegaly; Assessment of the clinical use of growth hormone receptor...

  • Preoperative preparation of patients with pituitary gland disorders. Malenković, Vesna; Gvozdenović, Ljiljana; Milaković, Branko; Sabljak, Vera; Ladjević, Nebojša; Živaljević, Vladan // Acta Chirurgica Iugoslavica;2011, Vol. 58 Issue 2, p91 

    This paper presents the most common disorders of pituitary function: acromegaly, hypopituitarism, diabetes insipidus and syndrome similar to diabetes insipidus, in terms of their importance in preoperative preparation of patients. Pituitary function manages almost the entire endocrine system...

  • Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Adelman, Daphne T.; Liebert, Karen J. P.; Nachtigall, Lisa B.; Lamerson, Michele; Bakker, Bert // International Journal of General Medicine;2013, Vol. 6, p31 

    Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease...

  • Treatment of Acromegaly with the Growth Hormone—Receptor Antagonist Pegvisomant. Trainer, Peter J.; Drake, William M.; Katznelson, Laurence; Freda, Pamela U.; Herman-Bonert, Vivien; van der Lely, A.J.; Dimaraki, Eleni V.; Stewart, Paul M.; Friend, Keith E.; Vance, Mary Lee; Besser, G. Michael; Thorner, Michael O.; Parkinson, Craig; Klibanski, Anne; Powell, Jeffrey S.; Barkan, Ariel L.; Sheppard, Michael C.; Maldonado, Mario; Rose, D. Roderick; Clemmons, David R. // New England Journal of Medicine;04/20/2000, Vol. 342 Issue 16, p1171 

    Background: Patients with acromegaly are treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone–receptor antagonist that blocks...

  • Does Apolipoprotein E genotype affect cardiovascular risk in subjects with acromegaly? Bozok Cetintas, Vildan; Zengi, Ayhan; Tetik, Asli; Karadeniz, Muammer; Ergonen, Faruk; Kucukaslan, Ali; Tamsel, Sadik; Kosova, Buket; Sahin, Serap; Saygılı, Fusun; Eroglu, Zuhal // Endocrine (1355008X);Jun2012, Vol. 41 Issue 3, p465 

    Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone after epiphyseal closure at puberty. Usually, subjects with acromegaly exhibit a 2- to 3-fold higher mortality rate from diseases that are associated with cardiovascular complications when compared to...

  • Section II hormonal causes. Sotos, Juan F. // Clinical Pediatrics;Nov1996, Vol. 35 Issue 11, p579 

    Focuses on excessive secretion of growth hormones. Pituitary gigantism and acromegaly; Manifestations in gigantism and acromegaly.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics